Molbio Diagnostics Share Price: Stock Lists at 21% Premium Over IPO Price on August 17, 2026

Molbio Diagnostics shares listed at a 21% premium over the initial public offering (IPO) price of ₹807.  

On National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) the stock began trading at ₹980 on August 17, 2026, compared to the IPO price of ₹807. 

Strong Market Debut for Molbio Diagnostics 

Ccompared to its IPO issue price,  Molbio Diagnostics' shares opened at ₹980, showing a gain of 21.44%. 

The IPO oversubscribed 70.27 times, garnering bids for 57,32,14,392 shares against 81,58,529 shares offered.  

The company's market capitalisation reached approximately ₹11,293.52 crore by listing at ₹980. 

Oversubscription and Demand Analysis 

The IPO was launched on August 10, 2026, and closed on August 12, 2026. Different investor categories have attracted substantial demand.  

Qualified Institutional Buyers (QIBs) showed the most considerable interest, subscribing 186.39 times, while Non-Institutional Investors (NIIs) subscribed 49.80 times. The retail segment was subscribed 12.96 times. This robust demand surpassed the grey market premium prediction, which indicated a 14.37% rise over the issue price. 

Utilisation of IPO Proceeds 

Molbio Diagnostics has earmarked ₹105.54 crore from the fresh issue for capital expenditure, focusing on establishing research facilities and Centres of Excellence.  

Additionally, ₹72.28 crore is set aside for acquiring plant and machinery for its units in Goa and Visakhapatnam. The remainder will be used for general corporate needs. The IPO consisted of a ₹200 crore fresh issue and a ₹739.70 crore offer for sale. 

Read More: Transformers and Rectifiers India Share Price Surges; Receives Large Order from APTRANSCO! 

Company Profile and Market Impact 

Gaining popularity for its Truenat platform, a portable PCR testing system, Molbio Diagnostics is a leader in providing point-of-care diagnostics.  

With testing solutions for over 30 diseases, the company operates 5 manufacturing facilities across India. Its products are utilised by public healthcare organisations, hospitals, laboratories, and other medical institutions. 

Molbio Diagnostics Share Price Performance 

As of August 17, 2026, at 11:47 AM, Molbio Diagnostics share price on NSE was trading at ₹996.15, up by 23.44% over the IPO price of ₹807. 

Conclusion 

Shares of Molbio Diagnostics debuted at a 21% premium at ₹980, compared to the IPO price of ₹807. The IPO, which was oversubscribed by 70.27 times, reflects a keen interest from various investor segments, enhancing its market capitalisation to approximately ₹11,293.52 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.